I saw that article. I think the important factor to remember is that trail design is much better and if a drug can get through Phase 3 clinical trials and meet their endpoints, it is pretty much a given the drug will get approved unless there are severe side effects.

In the mean time, looks like no one has an answer to my previous question. No wonder why the stock is in the gutter.